Vitamin D in patients with chronic kidney disease: a position statement of the Working Group “Trace Elements and Mineral Metabolism” of the Italian Society of Nephrology

2016 ◽  
Vol 29 (3) ◽  
pp. 305-328 ◽  
Author(s):  
Luigi Francesco Morrone ◽  
Pergiorgio Bolasco ◽  
Corrado Camerini ◽  
Giuseppe Cianciolo ◽  
Adamasco Cupisti ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Trace Elements ◽  
Kidney Disease ◽  
Working Group ◽  
Mineral Metabolism ◽  
Position Statement ◽  
Italian Society

scholarly journals Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Luciana Gravellone ◽  
Maria Antonietta Rizzo ◽  
Valentina Martina ◽  
Nicoletta Mezzina ◽  
Anna Regalia ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Mineral Metabolism ◽  
Controlled Trial ◽  
Protective Role ◽  
Hemodialysis Patients ◽  
Vitamin D Metabolites ◽  
Beneficial Effects

Vitamin D deficiency appears to be an underestimated risk factor for cardiovascular disease in patients with chronic kidney disease. Evidence from both basic science and clinical studies supports the possible protective role of vitamin D beyond its effect on mineral metabolism. Toxicity of pharmacologic doses of active vitamin D metabolites, in particular calcitriol, is mainly due to the possibility of positive calcium and phosphorus balance. Therefore, vitamin D analogs have been developed, which suppress PTH secretion and synthesis with reduced calcemic and phosphatemic effects. Observational studies suggest that in hemodialysis patients the use of a vitamin D receptor (VDR) activator, such as calcitriol, doxercalciferol, paricalcitol, or alfacalcidol, is associated with a reduced mortality when compared with nonusers of any VDR activator. In this article the existing literature on the topic is reviewed, although a more robust answer to the question of whether or not VDR activators have beneficial effects in hemodialysis patients will hopefully come from a randomized controlled trial.

A new role for vitamin D receptor activation in chronic kidney disease

2009 ◽  
Vol 297 (6) ◽  
pp. F1502-F1509 ◽  
Author(s):  
José M. Valdivielso ◽  
Jorge Cannata-Andía ◽  
Blai Coll ◽  
Elvira Fernández
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Receptor ◽  
Mineral Metabolism ◽  
Receptor Activation ◽  
Left Ventricular ◽  
Traditional Use ◽  
Transplant Patients ◽  
Therapeutic Uses

Vitamin D has proven to be much more than a simple “calcium hormone.” The fact that the vitamin D receptor has been found in cells not related to mineral metabolism supports that statement. The interest of nephrologists in vitamin D and its effects beyond mineral metabolism has increased over the last few years, evidencing the importance of this so-called “sunshine hormone.” In the present review, we highlight the most recent developments in the traditional use of vitamin D in chronic kidney disease (CKD) patients, namely, the control of secondary hyperparathyroidism (sHPT). Furthermore, we also explore the data available regarding the new possible therapeutic uses of vitamin D for the treatment of other complications present in CKD patients, such as vascular calcification, left ventricular hypertrophy, or proteinuria. Finally, some still scarce but very promising data regarding a possible role of vitamin D in kidney transplant patients also are reviewed. The available data point to a potential beneficial effect of vitamin D in CKD patients beyond the control of mineral metabolism.

scholarly journals Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease – Position Statement of the Working Group of the Polish Society of Nephrology

2018 ◽  
Vol 43 (3) ◽  
pp. 959-969 ◽  
Author(s):  
Marcin Adamczak ◽  
Anna Masajtis-Zagajewska ◽  
Oktawia Mazanowska ◽  
Katarzyna Madziarska ◽  
Tomasz Stompór ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Metabolic Acidosis ◽  
Kidney Disease ◽  
Working Group ◽  
Position Statement ◽  
Diagnosis And Treatment ◽  
Polish Society

scholarly journals Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

2008 ◽  
Vol 24 (2) ◽  
pp. 348-354 ◽  
Author(s):  
F. Locatelli ◽  
A. Covic ◽  
K.-U. Eckardt ◽  
A. Wiecek ◽  
R. Vanholder ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Working Group ◽  
Best Practice ◽  
Position Statement ◽  
Anaemia Management

scholarly journals Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease

2018 ◽  
Vol 33 (12) ◽  
pp. 2208-2217 ◽  
Author(s):  
Christian Lerch ◽  
Rukshana Shroff ◽  
Mandy Wan ◽  
Lesley Rees ◽  
Helen Aitkenhead ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Mineral Metabolism ◽  
Vitamin D Supplementation ◽  
Nutritional Vitamin

scholarly journals Vitamin D Metabolism and Its Role in Mineral and Bone Disorders in Chronic Kidney Disease in Humans, Dogs and Cats

Metabolites ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 499
Author(s):  
Fernanda C. Chacar ◽  
Márcia M. Kogika ◽  
Rafael V. A. Zafalon ◽  
Marcio A. Brunetto
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Deficiency ◽  
Comparative Studies ◽  
Mineral Metabolism ◽  
Vitamin D Metabolism ◽  
Bone Disorders

Some differences regarding Vitamin D metabolism are described in dogs and cats in comparison with humans, which may be explained by an evolutionary drive among these species. Similarly, vitamin D is one of the most important regulators of mineral metabolism in dogs and cats, as well as in humans. Mineral metabolism is intrinsically related to bone metabolism, thus disturbances in vitamin D have been implicated in the development of chronic kidney disease mineral and bone disorders (CKD-MBD) in people, in addition to dogs and cats. Vitamin D deficiency may be associated with Renal Secondary Hyperparathyroidism (RSHPT), which is the most common mineral disorder in later stages of CKD in dogs and cats. Herein, we review the peculiarities of vitamin D metabolism in these species in comparison with humans, and the role of vitamin D disturbances in the development of CKD-MBD among dogs, cats, and people. Comparative studies may offer some evidence to help further research about vitamin D metabolism and bone disorders in CKD.

scholarly journals Pharmacotherapy in chronic kidney disease hyperphosphatemia – effects on vascular calcification and bone health

2017 ◽  
Vol 63 (01) ◽  
pp. 3-24
Author(s):  
Dimce Dzingarski ◽  
Kristina Mladenovska
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Bone Health ◽  
Mineral Metabolism ◽  
Phosphate Binders ◽  
Active Vitamin ◽  
Bone Disorders ◽  
Active Vitamin D ◽  
Active Vitamin D Sterols

Hyperphosphatemia (HP) in patients with chronic kidney disease (CKD) leads to complications such as renal osteodistrophy, cardiovascular calcification and hemodynamic abnormalities, all of them having a serious impact on the survival rate and quality of life. Also, HP is a key pathogenic factor in the development of secondary hyperparathyroidism (SHPT) in CKD. Having in regard the significance of controlling serum phosphorus levels (Pi), in this paper, the needs and obstacles to successful pharmacological management of HP in CKD are presented, with an overview of major classes of phosphate binders (PBs) and other drugs affecting Pi level, such as active vitamin D sterols and calcimimetics (CMs). In addition, their effects on progression of cardiovascular calcification and bone health are elaborated. In this regard, a PubMed search was carried out to capture all abstracts and articles relevant to the topic of CKD, HP and mineral metabolism, bone disorders and vascular/valvular calcification (VC), published from January 2007 to August 2017. The search was limited to English language, with the search terms including drug name AND hyperphosphatemia or cardiovascular calcification or bone disorder. Comparative studies, clinical studies/trials and meta-analyses related to different classes/representatives of PBs, vitamin D analogues and CMs were reviewed and research data related to their efficacy and safety compared. Keywords: chronic kidney disease, hyperphosphatemia, phosphate binders, active vitamin D sterols, calcimimetics, bone disorders, cardiovascular calcification

Sign in / Sign up

Export Citation Format

Share Document